Harpoon Therapeutics, Inc.

Amgen Inc.

Amgen Research (munich) Gmbh

Washington University

Takeda Pharmaceutical Company Limited

Tularik Limited

Tcr2 Therapeutics Inc.

Werewolf Therapeutics, Inc.

Amgen Research Gmbh

Holger Wesche

Richard J Austin

Bryan D Lemon

Patrick A Baeuerle

Robert B Dubridge

Jeanmarie Guenot

Luke Evnin

Peter Kufer

Tobias Raum

Chadwick Terence King

Patrick Hoffmann

Doris Rau

Ralf Lutterbüse

Vanitha Ramakrishnan

Brian Mingtung Chan

David V Goeddel

Vinay Bhaskar

Daniel Hicklin

Roman Kischel

William Winston

Cynthia Seidel-Dugan

Shouhua Xiao

Dineli Wickramasinghe

M Shawn Jeffries

Pui Seto

Shyun Li

Robert Hofmeister

Gregory Sieczkiewicz

Jose Andres Salmeron Garcia

Zheng Pan

Ralf Lutterbuese

Robert D Schreiber

Maia Vinogradova

Steven Teitelbaum

Anand Panchal

Shuoyen Jack Lin

Kathryn Kwant

Sony S Rocha

Kevin Wright

Heather Brodkin

Patrick Baeuerle

Provided are antibody constructs comprising a first human binding domain capable of binding to human CDH19 on the surface of a target cell and a second domain capable of binding to human CD3 on the surface of a T cell. Also provided are nucleic acids encoding the antibody constructs, vectors comprising the nucleic acids, and host cells transformed or transfected with the vectors. Further provided are a process for the production of the antibody constructs, methods of using the antibody constructs and a kit comprising the antibody constructs.

Antibody constructs for CDH19 and CD3

Disclosed herein are binding moieties that comprise non-CDR loops for masking the binding of a binding molecule to its target and CDRs for binding bulk serum proteins. Conditionally active target binding proteins that contain the binding moieties are also provided. Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of using such formulations are further provided.

Binding moiety for conditional activation of immunoglobulin molecules

Provided herein are B cell maturation agent (BCMA) targeting trispecific proteins comprising a domain binding to CD3, a half-life extension domain, and a domain binding to BCMA. Also provided are pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such BCMA targeting trispecific proteins. Also disclosed are methods of using the disclosed BCMA targeting trispecific proteins in the prevention, and/or treatment diseases, conditions and disorders.

Trispecific proteins and methods of use

Provided herein are EGFR binding proteins and EGFR targeting trispecific proteins comprising a domain binding to CD3, a half-life extension domain, and a domain binding to EGFR. Also provided are pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such EGFR binding proteins, EGFR targeting trispecific proteins. Also disclosed are methods of using the disclosed EGFR binding proteins, EGFR targeting trispecific proteins in the prevention, and/or treatment diseases, conditions and disorders.

EGFR binding proteins and methods of use

The invention relates to COnditional Bispecific Redirected Activation constructs, or COBRAs, that are administered in an active pro-drug format. Upon exposure to tumor proteases, the constructs are cleaved and activated, such that they can bind both tumor target antigens (TTAs) as well as CD3, thus recruiting T cells expressing CD3 to the tumor, resulting in treatment.

Constrained conditionally activated binding proteins

Provided herein are trispecific antigen-binding proteins comprising a domain binding to CD3, a half-life extension domain, and a domain binding to a target antigen. Also provided are pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such trispecific antigen-binding proteins. Also disclosed are methods of using the disclosed trispecific antigen-binding proteins in the prevention, and/or treatment diseases, conditions and disorders.

Trispecific binding proteins and methods of use

Disclosed herein are B cell maturation antigen binding proteins with improved binding affinities and improved ability to mediate killing of cancer cells expressing B cell maturation antigen (BCMA). Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of treatment of a cancer or a metastasis thereof using such formulations are further provided.

B cell maturation antigen binding proteins

Provided herein are DLL3 binding proteins and DLL3 targeting multispecific proteins (e.g., DLL3 targeting trispecific protein) comprising a domain binding to CD3, a half-life extension domain, and a domain binding to DLL3 (such as a DLL3 binding protein as provided herein). Also provided are pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such DLL3 binding proteins, DLL3 targeting trispecific proteins. Also disclosed are methods of using the disclosed DLL3 binding proteins, DLL3 targeting trispecific proteins in the prevention, and/or treatment diseases, conditions and disorders.

DLL3 binding proteins and methods of use

Disclosed herein are MSLN binding proteins with improved binding affinities and improved ability to mediate T cell dependent killing of cancer cells expressing mesothelin. Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of using such formulations are further provided.

Mesothelin binding proteins

Disclosed herein are inducible monovalent target-binding proteins which are activated upon protease cleavage. Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of using such formulations are further provided.

Inducible monovalent antigen binding protein

The invention provides a bispecific antibody construct comprising a first human binding domain capable of binding to human CDH19 on the surface of a target cell and a second domain capable of binding to human CD3 on the surface of a T cell. Moreover, the invention provides a nucleic acid encoding the antibody construct, a vector comprising the nucleic acid and a host cell transformed or transfected with the vector. Furthermore, the invention provides a process for the production of the bispecific antibody construct, a medical use of the antibody construct and a kit comprising the antibody construct. The bispecific antibody construct may be useful in the treatment of melanoma.

Provided herein are FLT3 binding proteins, pharmaceutical compositions comprising such proteins or fragments thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such FLT3 binding proteins. Also disclosed are methods of using the disclosed FLT3 binding proteins in the prevention, and/or treatment of diseases, conditions and disorders.

FLT3 binding proteins and methods of use

Provided herein are T-cell receptor (TCR) fusion proteins (TFPs), T-cells engineered to express one or more TFPs, and methods of use thereof for the treatment of diseases, including cancer.

Compositions and methods for TCR reprogramming using fusion proteins

Growing community of inventors

San Francisco, CA, United States of America

Holger Wesche